---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-006889"
form_type: "8-K"
ticker: null
cik: "0001029125"
company_name: "Panbela Therapeutics, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:03:29.574079+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Nasdaq delists Panbela Therapeutics; trading suspended March 7, 2024

## Summary
- Nasdaq notified Panbela of delisting due to failure to meet $2.5M stockholders' equity requirement.
- Trading suspended at open on March 7, 2024; stock expected to quote on OTC Pink Market under PBLA.
- Company has 15 days to request review of Panel's decision by Nasdaq Listing Council.
- Company plans to continue filing periodic reports with SEC despite delisting.

## SEC filing metadata
- accession: 0001437749-24-006889
- form_type: 8-K
- cik: 0001029125
- company_name: Panbela Therapeutics, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1029125/000143774924006889/0001437749-24-006889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029125/000143774924006889/pbla20240306_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-006889
- JSON: https://secwatch.observer/filing/0001437749-24-006889.json
- Plain text: https://secwatch.observer/filing/0001437749-24-006889.txt

## Key facts
- Listing & Compliance Notices
  Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1), 5550(b)
  source text: s have lapsed. In the interim, the Company expects its common stock will be eligible for quotation on the OTC Pink Market under its existing symbol, “PBLA.” The Panel reached its decision because the Company is in violation of the minimum $2.5 million stockholders equity requirement in Listing Rule 5550(b)(1) and unable to comply with any of the alternative requirements in Listing Rule 5550(b). The Company has 15 days after the date it received notice of the Panel’s decision to request that the Nasdaq Listing and Hearing Review Council review the decision, or the Council may, on its own motion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774924006889/0001437749-24-006889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.